Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte–Associated Antigen 4 Monoclonal Antibody CP-675,206

Cancer immunoediting: from immunosurveillance to tumor escape

Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393 · see citing works

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914 · see citing works

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · see citing works

Lymphoproliferative Disorders with Early Lethality in Mice Deficient in <i>Ctla-4</i>

Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · see citing works

Cancer regression and autoimmunity induced by cytotoxic t lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · see citing works

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Middleton, M. R., Grob, J., Aaronson, N. K., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M. E., Aamdal, S., Cebon, J. S., Coates, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.158 · Cited by 1,270 · see citing works

CTLA-4–Ig regulates tryptophan catabolism in vivo

Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,160 · see citing works

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · see citing works

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · see citing works

CTLA-4-Mediated Inhibition in Regulation of T Cell Responses: Mechanisms and Manipulation in Tumor Immunotherapy

Chambers, C. A., Kuhns, M. S., Egen, J. G., & Allison, J. P. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.565 · Cited by 1,000 · see citing works

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes

Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852 · see citing works

Metabolic properties of IgG subclasses in man

Morell, A., Terry, W. D., & Waldmann, T. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106279 · Cited by 530 · see citing works

Autoimmunity in a Phase I Trial of a Fully Human Anti-Cytotoxic T-Lymphocyte Antigen-4 Monoclonal Antibody With Multiple Melanoma Peptides and Montanide ISA 51 for Patients With Resected Stages III and IV Melanoma

Sanderson, K. M., Scotland, R., Lee, P. P., Liu, D., Groshen, S. G., Snively, J., Sian, S., Nichol, G. M., Davis, T. A., Keler, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.128 · Cited by 432 · see citing works

Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease

Paust, S., Lu, L., McCarty, N., & Cantor, H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403342101 · Cited by 328 · see citing works

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials

Eigentler, T., Caroli, U. M., Radny, P., & Garbe, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01280-4 · Cited by 323 · see citing works

IN VIVO CELL ACTIVATION FOLLOWING OKT3 ADMINISTRATION

Chatenoud, L., Ferran, C. J., Legendre, C. M., Thouard, I., Merite, S., REUTER, A. M., Gevaert, Y., Kreis, H., Franchimont, P., & Bach, J. (1990) · Transplantation · doi:10.1097/00007890-199004000-00009 · Cited by 319 · see citing works

Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma

Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E., & Rosenberg, S. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3477 · Cited by 302 · see citing works

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.

Falkson, C. I., Ibrahim, J. G., Kirkwood, J. M., Coates, A. S., Atkins, M. B., & Blum, R. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1743 · Cited by 302 · see citing works

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase

Mellor, A. L. (2004) · International Immunology · doi:10.1093/intimm/dxh140 · Cited by 288 · see citing works

Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance

Byrd, J. C., Waselenko, J. K., Maneatis, T. J., Murphy, T. J., Ward, F. T., Monahan, B. P., Sipe, M. A., Donegan, S., & White, C. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.791 · Cited by 264 · see citing works

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.

Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257 · see citing works

The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky memorial lecture

DeVita, V. T. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1 · Cited by 164 · see citing works

Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques

Keler, T., Halk, E., Vitale, L. A., O’Neill, T., Blanset, D. L., Lee, S., Srinivasan, M., Graziano, R. F., Davis, T. A., Lönberg, N., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.6251 · Cited by 134 · see citing works

Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy

Ribas, A., Glaspy, J. A., Lee, Y., Dissette, V. B., Seja, E., Vu, H. T., Tchekmedyian, N. S., Oseguera, D. K., Comin-Anduix, B., Wargo, J. A., et al. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200409000-00004 · Cited by 119 · see citing works

Expression of CTLA‐4 by Human Monocytes

Wang, X. ‐., Giscombe, R., Yan, Z., Heiden, T., Xu, D., & Lefvert, A. K. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.0300-9475.2001.01019.x · Cited by 90 · see citing works

IFN-gamma regulates murine interferon-inducible T cell alpha chemokine (I-TAC) expression in dendritic cell lines and during experimental autoimmune encephalomyelitis (EAE).

Hamilton, N. H. R., Banyer, J., Hapel, A. J., Mahalingam, S., Ramsay, A. J., Ramshaw, I. A., & Thomson, S. A. (2002) · PubMed · Cited by 87 · see citing works

Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Can Regulate Dendritic Cell–induced Activation and Cytotoxicity of CD8+ T Cells Independently of CD4+T Cell Help

McCoy, K. D., Hermans, I. F., Fraser, J., Gros, G. S. L., & Ronchese, F. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1157 · Cited by 70 · see citing works

Association of Asthma Severity and Bronchial Hyperresponsiveness With a Polymorphism in the Cytotoxic T-Lymphocyte Antigen-4 Gene

Lee, S. Y., Lee, Y. H., Shin, C., Shim, J. J., Kang, K. H., Yoo, S. H., & In, K. H. (2002) · CHEST Journal · doi:10.1378/chest.122.1.171 · Cited by 67 · see citing works

Patients With Melanoma Metastases at Cutaneous and Subcutaneous Sites Are Highly Susceptible to Interleukin-2–Based Therapy

Chang, E., & Rosenberg, S. A. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200101000-00010 · Cited by 45 · see citing works

Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.

Hanson, D. C., Canniff, P. C., Primiano, M. J., Donovan, C. B., Gardner, J. P., Natoli, E. J., Morgan, R. W., Mather, R. J., Singleton, D. H., Hermes, P., et al. (2004) · Cancer Research · Cited by 37 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

Immune Checkpoint Blockade in Cancer Therapy

Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,736 · see citing works

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · see citing works

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648 · see citing works

PD-1 and PD-1 ligands: from discovery to clinical application

Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · see citing works

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

Das, S., & Johnson, D. B. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0805-8 · Cited by 1,145 · see citing works

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · see citing works

Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review

Khoja, L., Day, D., Chen, T. W., Siu, L. L., & Hansen, A. R. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx286 · Cited by 937 · see citing works

Coinhibitory Pathways in Immunotherapy for Cancer

Baumeister, S. H. C., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 912 · see citing works

T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis

Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 820 · see citing works

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

Ribas, A., Kefford, R. F., Marshall, M. A., Punt, C. J. A., Haanen, J. B. A. G., Mármol, M., Garbe, C., Gogas, H. J., Schachter, J., Linette, G. P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.6112 · Cited by 802 · see citing works

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715 · see citing works

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704 · see citing works

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697 · see citing works

CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

Ott, P. A., Hodi, F. S., & Robert, C. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0143 · Cited by 689 · see citing works

Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.

Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685 · see citing works

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

Hodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · see citing works

Immunostimulatory monoclonal antibodies for cancer therapy

Melero, I., Hervás‐Stubbs, S., Glennie, M. J., Pardoll, D. M., & Chen, L. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2051 · Cited by 626 · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602 · see citing works

Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

Garbe, C., Eigentler, T., Keilholz, U., Hauschild, A., & Kirkwood, J. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0190 · Cited by 581 · see citing works

Checkpoint Blockade in Cancer Immunotherapy

Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 577 · see citing works

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Korman, A. J., Garrett-Thomson, S. C., & Lönberg, N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 561 · see citing works

Clinical Activity and Immune Modulation in Cancer Patients Treated With CP-870,893, a Novel CD40 Agonist Monoclonal Antibody

Vonderheide, R. H., Flaherty, K. T., Khalil, M., Stumacher, M., Bajor, D. L., Hutnick, N. A., Sullivan, P., Mahany, J. J., Gallagher, M., Kramer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3311 · Cited by 513 · see citing works

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

Brody, J., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M. A., Advani, R. H., Kim, Y. H., Hoppe, R. T., Knox, S. J., Shin, L. K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9793 · Cited by 489 · see citing works

Targeting T Cell Co-receptors for Cancer Therapy

Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 468 · see citing works

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463 · see citing works

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Kelley, R. K., Sangro, B., Harris, W. P., Ikeda, M., Okusaka, T., Kang, Y., Qin, S., Tai, D. W.-M., Lim, H. Y., Yau, T. C. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03555 · Cited by 450 · see citing works

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 439 · see citing works

Cancer immunotherapy – revisited

Lesterhuis, W. J., Haanen, J. B. A. G., & Punt, C. J. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3500 · Cited by 426 · see citing works

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Maio, M., Scherpereel, A., Calabrò, L., Aerts, J. G. J. V., Cedrés, S., Bearz, A., Nackaerts, K., Fennell, D. A., Kowalski, D. M., Tsao, A. S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30446-1 · Cited by 422 · see citing works

Endocrine Side Effects Induced by Immune Checkpoint Inhibitors

Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403 · see citing works

A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors

de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381 · see citing works

Dendritic Cell–Based Immunotherapy: State of the Art and Beyond

Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M., & Figdor, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1399 · Cited by 379 · see citing works

CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire

Robert, L., Tsoi, J., Wang, X., Emerson, R., Homet, B., Chodon, T., Mok, S., Huang, R., Cochran, A. J., Comı́n-Anduix, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2648 · Cited by 373 · see citing works

Immunotherapy for lung cancer

Steven, A. K., Fisher, S. A., & Robinson, B. W. S. (2016) · Respirology · doi:10.1111/resp.12789 · Cited by 342 · see citing works

CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 335 · see citing works

The B7 Family and Cancer Therapy: Costimulation and Coinhibition

Zang, X., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1030 · Cited by 335 · see citing works

Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment

Fong, L. H., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 320 · see citing works

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

Oh, D.-Y., Lee, K.-H., Lee, D.-W., Yoon, J., Kim, T.-Y., Bang, J.-H., Nam, A.-R., Oh, K.-S., Kim, J.-M., Lee, Y., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00043-7 · Cited by 321 · see citing works

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

Camacho, L. H., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Gajewski, T. F., Redman, B. G., Pavlov, D., Bulanhagui, C. A., Bozon, V. A., Gómez-Navarro, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2435 · Cited by 309 · see citing works

Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)

O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309 · see citing works

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

Siu, L. L., Even, C., Mesı́a, R., Remenár, É., Daste, A., Delord, J., Krauß, J., Saba, N. F., Nabell, L. M., Ready, N., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4628 · Cited by 308 · see citing works

Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer

Chung, K. Y., Gore, I., Fong, L. H., Venook, A. P., Beck, S. B., Dorazio, P., Criscitiello, P. J., Healey, D. I., Huang, B., Gómez-Navarro, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3994 · Cited by 307 · see citing works

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

Hersh, E. M., O'Day, S. J., Powderly, J. D., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Samlowski, W. E., Nichol, G. M., Yellin, M. J., & Weber, J. S. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9376-8 · Cited by 305 · see citing works

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

Vonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D. K., Soulières, D., Dorazio, P., Trosko, J. A., Rüter, J., Mariani, G. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0505 · Cited by 301 · see citing works

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

Dillard, T. H., Yedinak, C. G., Alumkal, J. J., & Fleseriu, M. (2009) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 296 · see citing works

Molecularly targeted cancer therapy: some lessons from the past decade

Huang, M., Shen, A., Ding, J., & Geng, M. (2013) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 289 · see citing works

Costimulatory and coinhibitory receptors in anti‐tumor immunity

Driessens, G., Kline, J. P., & Gajewski, T. F. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00771.x · Cited by 284 · see citing works

Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse Events

Weber, J. S. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-864 · Cited by 284 · see citing works

Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events

González-Rodríguez, E., Rodríguez‐Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 251 · see citing works

The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation

Wolchok, J. D., & Saenger, Y. M. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-2 · Cited by 250 · see citing works

Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy

Callahan, M. K., Wolchok, J. D., & Allison, J. P. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.001 · Cited by 243 · see citing works

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

Kirkwood, J. M., Lorigan, P. C., Hersey, P., Hauschild, A., Robert, C., McDermott, D. F., Marshall, M. A., Gómez-Navarro, J., Liang, J. Q., & Bulanhagui, C. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2033 · Cited by 241 · see citing works

Improving T Cell Therapy for Cancer

Leen, A. M., Rooney, C. M., & Foster, A. E. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141527 · Cited by 238 · see citing works

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

Pennock, G. K., & Chow, L. Q. M. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0422 · Cited by 236 · see citing works

Next Generation of Immunotherapy for Melanoma

Kirkwood, J. M., Tarhini, A. A., Panelli, M. C., Moschos, S. J., Zarour, H. M., Butterfield, L. H., & Gogas, H. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.6423 · Cited by 229 · see citing works

Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 228 · see citing works

Metastatic Melanoma – A Review of Current and Future Treatment Options

Maverakis, E., Cornelius, L. A., Bowen, G., Phan, T., Patel, F., Fitzmaurice, S., He, Y., Burrall, B. A., Duong, C., Kloxin, A. M., et al. (2014) · Acta Dermato Venereologica · doi:10.2340/00015555-2035 · Cited by 227 · see citing works

Chemotherapy for metastatic melanoma

Gogas, H. J., Kirkwood, J. M., & Sondak, V. K. (2007) · Cancer · doi:10.1002/cncr.22427 · Cited by 223 · see citing works

Mitigating the toxic effects of anticancer immunotherapy

Gangadhar, T. C., & Vonderheide, R. H. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.245 · Cited by 222 · see citing works

Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review

Joshi, M., Whitelaw, B., Palomar, M. T. P., Wu, Y., & Carroll, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 224 · see citing works

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

Aglietta, M., Barone, C. A., Sawyer, M. B., Moore, M. J., Miller, W. H., Bagalá, C., Colombi, F., Cagnazzo, C., Gioeni, L., Wang, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu205 · Cited by 218 · see citing works

Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma

Ribas, A., Comı́n-Anduix, B., Chmielowski, B., Jalil, J., de la Rocha, P., McCannel, T. A., Ochoa, M. T., Seja, E., Villanueva, A., Oseguera, D. K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1254 · Cited by 217 · see citing works

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

Bluemel, C., Hausmann, S., Fluhr, P., Sriskandarajah, M., Stallcup, W. B., Baeuerle, P. A., & Kufer, P. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0844-y · Cited by 205 · see citing works

Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma.

Oble, D. A., Loewe, R. P., Yu, P., & Mihm, M. C. (2009) · PubMed Central · Cited by 204 · see citing works

New immunotherapies targeting the PD-1 pathway

Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 190 · see citing works

Fully human antibodies from transgenic mouse and phage display platforms

Lönberg, N. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.004 · Cited by 189 · see citing works

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

von Euw, E., Chodon, T., Attar, N., Jalil, J., Koya, R. C., Comin-Anduix, B., & Ribas, A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-35 · Cited by 189 · see citing works

CD200 Expression on Tumor Cells Suppresses Antitumor Immunity: New Approaches to Cancer Immunotherapy

Kretz-Rommel, A., Qin, F., Dakappagari, N. K., Ravey, E. P., McWhirter, J. R., Oltean, D. I., Frederickson, S., Maruyama, T., Wild, M. A., Nolan, M. J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5595 · Cited by 175 · see citing works

Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma

Nevala, W. K., Vachon, C. M., Leontovich, A. A., Scott, C. G., Thompson, M. A., & Markovic, S. N. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1980 · Cited by 177 · see citing works

Endocrine side effects of cancer immunotherapy

Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177 · see citing works

CTLA‐4: a key regulatory point in the control of autoimmune disease

Scalapino, K. J., & Daikh, D. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00639.x · Cited by 175 · see citing works

Cancer immunotherapy

Baxevanis, C. N., Perez, S. A., & Papamichail, M. (2009) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360902937809 · Cited by 177 · see citing works

Development of immune checkpoint therapy for cancer

Fritz, J. M., & Lenardo, M. J. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20182395 · Cited by 175 · see citing works

Current systemic therapy for metastatic melanoma

Agarwala, S. S. (2009) · Expert Review of Anticancer Therapy · doi:10.1586/era.09.25 · Cited by 172 · see citing works

Thyroid Dysfunction from Antineoplastic Agents

Hamnvik, O. R., Larsen, P. R., & Marqusee, E. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr373 · Cited by 165 · see citing works

Potential targeting of B7‐H4 for the treatment of cancer

Podojil, J. R., & Miller, S. D. (2017) · Immunological Reviews · doi:10.1111/imr.12530 · Cited by 160 · see citing works

Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer

Ribas, A., Hanson, D. C., Noe, D. A., Millham, R., Guyot, D. J., Bernstein, S. H., Canniff, P. C., Sharma, A., & Gómez-Navarro, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-873 · Cited by 161 · see citing works

TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours

Conroy, H., Marshall, N. A., & Mills, K. H. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210910 · Cited by 159 · see citing works

Cancer Immunotherapy

Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 156 · see citing works

Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma

Rini, B. I., Stein, M. N., Shannon, P., Eddy, S., Tyler, A. J., Stephenson, J., Catlett, L., Huang, B., Healey, D. I., & Gordon, M. S. (2010) · Cancer · doi:10.1002/cncr.25639 · Cited by 154 · see citing works

Harnessing the Immune System for the Treatment of Non–Small-Cell Lung Cancer

Brahmer, J. R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8703 · Cited by 154 · see citing works

α-CTLA-4 mAb-associated Panenteritis

Oble, D. A., Mino-Kenudson, M. A., Goldsmith, J. D., Hodi, F. S., Seliem, R. M., Dranoff, G., Mihm, M. C., Hasserjian, R. P., & Lauwers, G. Y. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31817150e3 · Cited by 151 · see citing works

Trial Watch: Monoclonal antibodies in cancer therapy

Galluzzi, L., Vacchelli, E., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zucman‐Rossi, J., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.1.17938 · Cited by 150 · see citing works

Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

Pérez-De-Lis, M., Retamozo, S., Flores-Chávez, A., Kostov, B., Pérez-Álvarez, R., Brito‐Zerón, P., & Ramos‐Casals, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1372421 · Cited by 149 · see citing works

Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4

Dias, J. D., Hemminki, O., Diaconu, I., Hirvinen, M., Bonetti, A., Guse, K., Escutenaire, S., Kanerva, A., Pesonen, S. K., Loskog, A., et al. (2011) · Gene Therapy · doi:10.1038/gt.2011.176 · Cited by 149 · see citing works

Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment

Markovic, S. N., Erickson, L. A., Rao, R. D., Weenig, R. H., Pockaj, B. A., Bardia, A., Vachon, C. M., Schild, S. E., McWilliams, R. R., Hand, J. L., et al. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.4.490 · Cited by 149 · see citing works

Cytokine-Based Therapy and Biochemotherapy for Advanced Melanoma

Atkins, M. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2503 · Cited by 149 · see citing works

Cytotoxic T-Lymphocyte–Associated Antigen-4

Salama, A. K. S., & Hodi, F. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2232 · Cited by 148 · see citing works

Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma

Tarhini, A. A., Cherian, J., Moschos, S. J., Tawbi, H. A., Shuai, Y., Gooding, W. E., Sander, C., & Kirkwood, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.5394 · Cited by 148 · see citing works

B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis

Arigami, T., Narita, N., Mizuno, R., Nguyen, L., Ye, X., Chung, A. P., Giuliano, A. E., & Hoon, D. S. �. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181f1939d · Cited by 144 · see citing works

Biologic and immunomodulatory events after CTLA‐4 blockade with ticilimumab in patients with advanced malignant melanoma

Reuben, J. M., Lee, B.-N., Li, C., Gómez-Navarro, J., Bozon, V. A., Parker, C. A., Hernandez, I. M., Gutiérrez, C., Lopez‐Berestein, G., & Camacho, L. H. (2006) · Cancer · doi:10.1002/cncr.21854 · Cited by 144 · see citing works

Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy

Ma, C., Cheung, A. F., Chodon, T., Koya, R. C., Wu, Z., Ng, C., Avramis, E. V., Cochran, A. J., Witte, O. N., Baltimore, D., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0383 · Cited by 144 · see citing works

Reinvigorating exhausted CD8 + cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy

Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 136 · see citing works

Immunotherapy earns its spot in the ranks of cancer therapy

Pardoll, D. M., & Drake, C. G. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20112275 · Cited by 133 · see citing works

Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade

Ribas, A., Comı́n-Anduix, B., Economou, J. S., Donahue, T. R., de la Rocha, P., Morris, L. F., Jalil, J., Dissette, V. B., Shintaku, I. P., Glaspy, J. A., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0783 · Cited by 132 · see citing works

CTLA ‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

Camacho, L. H. (2015) · Cancer Medicine · doi:10.1002/cam4.371 · Cited by 132 · see citing works

Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies

Camacho, L. H., Ribas, A., Glaspy, J. A., Lopez‐Berestein, G., Reuben, J. M., Parker, C., Seja, E., Comı́n-Anduix, B., Bulanhagui, C. A., & Gómez-Navarro, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.2505 · Cited by 19 · see citing works

Anti-CTLA4 antibody clinical trials in melanoma

Ribas, A. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.09.001 · Cited by 51 · see citing works

Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma

Ribas, A., Bozon, V. A., Lopez‐Berestein, G., Pavlov, D., Reuben, J. M., Parker, C., Seja, E., Glaspy, J. A., Gómez-Navarro, J., & Camacho, L. H. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7524 · Cited by 31 · see citing works

A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum

Chung, K. Y., Gore, I., Fong, L. H., Venook, A. P., Dorazio, P., Healey, D. I., Pavlov, D., & Saltz, L. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3035 · Cited by 6 · see citing works

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

Ribas, A., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Redman, B. G., Gajewski, T. F., Pavlov, D., Bulanhagui, C. A., Navarro, J. G., & Camacho, L. H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3000 · Cited by 38 · see citing works